Kala Pharmaceuticals Shares Outstanding 2016-2021 | KALA

Kala Pharmaceuticals shares outstanding from 2016 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Kala Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2020 52
2019 34
2018 27
2017 11
2016 1
2015 1
Kala Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 65
2021-03-31 62
2020-12-31 52
2020-09-30 56
2020-06-30 56
2020-03-31 41
2019-12-31 34
2019-09-30 34
2019-06-30 34
2019-03-31 34
2018-12-31 27
2018-09-30 25
2018-06-30 25
2018-03-31 25
2017-12-31 11
2017-09-30 18
2017-06-30 1
2017-03-31 1
2016-12-31
2016-09-30 1
2016-06-30 1
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.192B $0.006B
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29